ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors.
about
Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin LymphomaHow I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus.Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.Initial staging of Hodgkin's disease: role of contrast-enhanced 18F FDG PET/CTDoes chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis.CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma.Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.Minimizing late effects in children and adults with Hodgkin lymphoma - the beginning of the end for radiation therapy.Clinical management of HIV-associated hematologic malignancies.Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study.Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis.Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support.The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD.Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis.Hodgkin's lymphoma--long-term outcome: an experience from a tertiary care cancer center in North India.G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.Impact of Provider Volume on Outcomes of Patients With Hodgkin Lymphoma.
P2860
Q34104990-806E8CFA-E3CC-4351-B931-BFB901E94127Q35038832-A482E81B-E1EA-482B-8F98-9791698565A9Q35103531-6EA2944F-B99D-4C5F-AA50-D7642418FBDAQ35986609-29497539-FE8D-4DF8-B561-CF0775AE524DQ36150877-10417253-0EE8-4707-8638-D92550EEEDFFQ36610747-EC77D635-4380-4663-B641-F4223A204CCEQ36973329-39B02FA8-99CD-4BE5-84F9-CDC36B36415BQ37126978-BD83909C-C62F-495D-9232-0C74F37459C3Q37138259-70C97A7F-855E-460D-A158-DFEF6E6EDD74Q37157419-2EE6F5FE-902D-4F27-8670-D15F2A8FEF3BQ38664912-59C4408C-95BA-46FF-B961-432C6F75E117Q40319011-015E4FDA-0BB1-4E10-B388-3745DCD7B1FDQ44462626-FC8DFB54-0D3E-41B4-A750-0381C05BBBAAQ46379382-C7FB9F37-BF4D-44B2-8C27-67EFBED2E548Q46394295-ECFBC6B9-E38F-4D65-99A9-6064F2C73E8DQ49276879-EAF4BFAC-0B86-485F-B7F2-8C8589368185Q50892830-0C0B352D-A8F3-48FF-8FD9-4073B3733122Q51456724-8775C6E4-D39B-4C8E-B68B-4188D7549077Q53485275-CAE4CEA2-7207-428B-B53A-9D39D1503EE9Q55435299-9C9AF927-7DC2-4897-BCB6-96C6602F2D6B
P2860
ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
ABVD for Hodgkin's lymphoma: f ...... reductions or growth factors.
@ast
ABVD for Hodgkin's lymphoma: f ...... reductions or growth factors.
@en
type
label
ABVD for Hodgkin's lymphoma: f ...... reductions or growth factors.
@ast
ABVD for Hodgkin's lymphoma: f ...... reductions or growth factors.
@en
prefLabel
ABVD for Hodgkin's lymphoma: f ...... reductions or growth factors.
@ast
ABVD for Hodgkin's lymphoma: f ...... reductions or growth factors.
@en
P356
P1433
P1476
ABVD for Hodgkin's lymphoma: f ...... reductions or growth factors.
@en
P2093
P304
P356
10.1093/ANNONC/MDL397
P577
2006-10-27T00:00:00Z